The safety of Dafiro has been evaluated in five controlled clinical studies with 5,175 patients, 2,613 of whom received valsartan in combination with amlodipine.
Dafiro ohutust on hinnatud viies kontrollrühmaga kliinilises uuringus, kus osales 5175 patsienti, kellest 2613 said valsartaani kombinatsioonis amlodipiiniga.